You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

INVELTYS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Inveltys patents expire, and when can generic versions of Inveltys launch?

Inveltys is a drug marketed by Alcon Labs Inc and is included in one NDA. There are twelve patents protecting this drug.

This drug has eighty-four patent family members in twelve countries.

The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Inveltys

A generic version of INVELTYS was approved as loteprednol etabonate by SENTISS on April 17th, 2019.

  Try a Trial

Summary for INVELTYS
Drug patent expirations by year for INVELTYS
Drug Prices for INVELTYS

See drug prices for INVELTYS

Pharmacology for INVELTYS
Anatomical Therapeutic Chemical (ATC) Classes for INVELTYS

US Patents and Regulatory Information for INVELTYS

INVELTYS is protected by thirteen US patents.

Patents protecting INVELTYS

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR TREATING OCULAR INFLAMMATION

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Alcon Labs Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for INVELTYS

See the table below for patents covering INVELTYS around the world.

Country Patent Number Title Estimated Expiration
Japan 2021001187 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 (COMPOSITIONS COMPRISING MULTIPLE COATED PARTICLES, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, AND METHODS OF FORMING THOSE PARTICLES) ⤷  Try a Trial
Australia 2018202074 Pharmaceutical nanoparticles showing improved mucosal transport ⤷  Try a Trial
Japan 7368661 ⤷  Try a Trial
New Zealand 742005 Pharmaceutical nanoparticles showing improved mucosal transport ⤷  Try a Trial
Australia 2013256092 Pharmaceutical nanoparticles showing improved mucosal transport ⤷  Try a Trial
Hong Kong 1208162 顯示提高的粘膜轉移的藥物納米粒子 (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2015066444 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.